Latitude Pharmaceuticals, Inc.

Dr. Reddy's Laboratories, Incorporated

Resq Pharmaceuticals LLC

Adventrx Pharmaceuticals, Inc.

Other

Farnam Companies, Inc.

Novalar Pharmaceuticals, Inc.

Mast Therapeutics, Inc.

Senju Pharmaceutical Co., Ltd.

Verastem, Inc.

Dara Biosciences, Inc.

Cardioklne, Inc

Cali Biosciences Us, LLC

Webb, Julie Ann

Sabino, Rafael Anthony

Andrew Xian Chen

Hailiang Chen

Franklin W Okumu

Balasingam Radhakrishnan

Wei Lin

Ben Esque

Eckard Weber

Jan-Jon Chu

Dushyanth Surakanti

Julius Knowles

Patricia D Kigin

Julie Ann Webb

Rafael Anthony Sabino

Mohammed Abdul Rahman

Masazumi Yamaguchi

Majid Keshtmand

Yali Jennifer Tsai

Kenneth James Ingold

Lijia Chen

Hai Liang Chen

Khawla Abu-Izza

Jun Fan

Christoph Schmidt

John Fan

James Cecil Free

Sally A Look

David L Bledsoe

Jianmin Xu

Damian McLOUD

Patricia Frech

John R Didsbury

Mohammad Saiful Islam

Norman Keith Orida

Linda Goff Jet

Franklin Okumu

Kenneth J Ingold

Linda Goff Jett

The present invention features methods and compositions for the intranasal, sublingual, and subcutaneous administration of bumetanide for the treatment of subjects suffering from edema refractory to oral diuretics.

Methods and compositions for treating edema refractory to oral diuretics

Use of an emulsion for pain relief comprising a local anesthetic, lecithin, oil and an aqueous phase, wherein local anesthetic is non-covalent bound to the emulsion oil droplets and the emulsion is physically and chemically stable and said emulsion provides better safety, extended release pharmacokinetics and a prolonged duration of action of the local anesthetic.

Emulsions for local anesthetics

This invention relates to clear one-phase liquid formulation vehicles comprising lecithin, MCT, bile salt and water.

Aqueous formulation for insoluble drugs

This invention relates to ready-to-use and safe solution compositions of glucagon suitable for administration by manual injection or by an insulin pump or other injection device to treat hypoglycemia. Said compositions comprise glucagon, an acid, anti-gelling polyol, a stabilizing-salt, viscosity reducer and an antioxidant, have a final pH between about 2 and 5, and is gel-free, chemically-stable, and pump-able.

Stabilized glucagon solutions

Sustained release spherical or non-spherical pellets comprising (a) an active ingredient (b) a wax-like agent, and (c) a spheronizing agent are provided. Oral dosage forms comprising the pellets and methods for preparing and using such pellets and dosage forms are also provided.

Sustained release compositions using wax-like materials

Sustained release compositions in tablet or multiparticulate forms comprising (a) an active ingredient, (b) a primary sustain release agent, (c) a wax-like agent, and (d) a bulking or spheronizing agent are provided. The compositions are chewable and/or taste masked. Oral dosage forms comprising such compositions and methods for preparing and using such compositions and dosage forms are also provided.

Chewable sustained release formulations

This invention relates to aqueous solution compositions of vancomycin that are stable, ready for use and do not require reconstitution.

Aqueous solution formulations of vancomycin

The present application provides parenteral compositions of diclofenac or its pharmaceutically acceptable salt and methods for making and using such compositions. Some of the compositions of the present application has one or more following properties: (1) ready to be injectable, (2) in the form of an oil-in-water emulsion, (3) stable under appropriate storage conditions, (4) containing therapeutically effective amount of diclofenac or its pharmaceutically acceptable salt, (5) sterilizable by filtration (6) containing components acceptable by regulatory agencies (e.g. the FDA), (7) containing low oil content and thus not exacerbating hyerlipidemia, and (8) is neither hyperallergenic nor vein irritating.

Parenteral diclofenac composition

This invention relates to compositions of glucagon suitable for administration by manual injection or by an insulin pump or other injection device to treat hypoglycemia. Said compositions comprise glucagon and a sugar, have a final pH between about 1.5 and 3, and are gel-free, chemically-stable at body temperature and pump-able.

Parenteral glucagon formulations

Parenteral (injectable) celecoxib emulsions and nanoemulsions are disclosed as are their use to treat pain in patients so afflicted. The emulsions are generally oil in water emulsions often comprised of an oil phase including an oil and a lecithin wherein the mean droplet size of the discontinuous oil phase is about 200 nanometers or less.

Parenteral compositions of celecoxib

The present invention provides a clear depot comprising at least one hydrophilic water-soluble pharmaceutically active agent selected from the group consisting of vancomycin, gentamicin, a pharmaceutically acceptable salt thereof and a mixture thereof, water, a phospholipid, an oil, optionally a pH adjusting agent, and a viscosity modifying agent selected from the group consisting of ethanol, isopropanol, and a mixture thereof, wherein the water present in the depot is no more than about 4 wt % relative to the total weight of the depot and the depot has a pH of between about 3 and about 6, method of making and administering same.

Phospholipid depot

Growing community of inventors

San Diego, CA, United States of America

Andrew Xian Chen